Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Antiandrogens  COVID-19 treatment studies for Antiandrogens  C19 studies: Antiandrogens  Antiandrogens   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 20% Improvement Relative Risk Severe case 2% Schmidt et al. Antiandrogens for COVID-19 Prophylaxis Is prophylaxis with antiandrogens beneficial for COVID-19? PSM retrospective 477 patients in the USA (March 2020 - February 2021) Lower mortality with antiandrogens (not stat. sig., p=0.41) Schmidt et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2021.34330 Favors various Favors control
Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19
Schmidt et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2021.34330
Schmidt et al., Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and.., JAMA Network Open, doi:10.1001/jamanetworkopen.2021.34330
Nov 2021   Source   PDF  
  All Studies   Meta
Retrospective 1,106 prostate cancer patients, showing no significant differences in COVID-19 outcomes with ADT.
risk of death, 20.4% lower, RR 0.80, p = 0.41, treatment 25 of 169 (14.8%), control 44 of 308 (14.3%), adjusted per study, odds ratio converted to relative risk, propensity score matching, multivariable.
risk of severe case, 2.0% lower, OR 0.98, p = 0.94, treatment 169, control 308, adjusted per study, propensity score matching, multivariable, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Schmidt et al., 12 Nov 2021, retrospective, USA, peer-reviewed, 42 authors, study period 17 March, 2020 - 11 February, 2021.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAntiandrogensAll
Abstract: Original Investigation | Urology Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19 Andrew L. Schmidt, MD; Matthew D. Tucker, MD; Ziad Bakouny, MD; Chris Labaki, MD; Chih-Yuan Hsu, PhD; Yu Shyr, PhD; Andrew J. Armstrong, MD; Tomasz M. Beer, MD; Ragneel R. Bijjula, MD; Mehmet A. Bilen, MD; Cindy F. Connell, MD, PhD; Scott Joseph Dawsey, MD; Bryan Faller, MD; Xin Gao, MD; Benjamin A. Gartrell, MD; David Gill, MD; Shuchi Gulati, MD; Susan Halabi, PhD; Clara Hwang, MD; Monika Joshi, MD; Ali Raza Khaki, MD; Harry Menon, MD; Michael J. Morris, MD; Matthew Puc, MD; Karen B. Russell, MD; Dimpy P. Shah, MD, PhD; Neil J. Shah, MD; Nima Sharifi, MD; Justin Shaya, MD; Michael T. Schweizer, MD; John Steinharter, MD; Elizabeth M. Wulff-Burchfield, MD; Wenxin Xu, MD; Jay Zhu, PhD; Sanjay Mishra, PhD; Petros Grivas, PhD; Brian I. Rini, MD; Jeremy Lyle Warner, MD; Tian Zhang, MD; Toni K. Choueiri, MD; Shilpa Gupta, MD; Rana R. McKay, MD; for the COVID-19 and Cancer Consortium Abstract Key Points IMPORTANCE Androgen deprivation therapy (ADT) has been theorized to decrease the severity of SARS-CoV-2 infection in patients with prostate cancer owing to a potential decrease in the tissuebased expression of the SARS-CoV-2 coreceptor transmembrane protease, serine 2 (TMPRSS2). OBJECTIVE To examine whether ADT is associated with a decreased rate of 30-day mortality from SARS-CoV-2 infection among patients with prostate cancer. Question Given the higher COVID-19– related mortality rate observed among men than among women, is androgen deprivation therapy associated with decreased rate of 30-day mortality from COVID-19 among patients with prostate cancer? DESIGN, SETTING, AND PARTICIPANTS This cohort study analyzed patient data recorded in the Findings In this cohort study of 1106 COVID-19 and Cancer Consortium registry between March 17, 2020, and February 11, 2021. The patients, no statistically significant consortium maintains a centralized multi-institution registry of patients with a current or past difference was found in the rates of all diagnosis of cancer who developed COVID-19. Data were collected and managed using REDCap cause 30-day mortality following software hosted at Vanderbilt University Medical Center in Nashville, Tennessee. Initially, 1228 COVID-19 infection among men with patients aged 18 years or older with prostate cancer listed as their primary malignant neoplasm were prostate cancer receiving androgen included; 122 patients with a second malignant neoplasm, insufficient follow-up, or low-quality data deprivation therapy (15%) vs those not were excluded. Propensity matching was performed using the nearest-neighbor method with a 1:3 receiving androgen deprivation ratio of treated units to control units, adjusted for age, body mass index, race and ethnicity, Eastern therapy (14%). Cooperative Oncology Group performance status score, smoking status, comorbidities Meaning The findings of this cohort (cardiovascular, pulmonary, kidney disease, and diabetes), cancer status, baseline steroid use, COVID-19 treatment, and presence of metastatic disease. study do not support an association between androgen deprivation therapy and 30-day mortality among patients EXPOSURES Androgen deprivation therapy use was defined as prior bilateral orchiectomy or with COVID-19 infection. pharmacologic ADT administered within the prior 3 months of presentation with..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop